Alicia Gutierrez-Valencia

Alicia Gutierrez-Valencia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alicia Gutierrez-Valencia has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Alexandre Pérez-González

    Group of Virology and Pathogenesis, Internal Medicine Department, Álvaro Cunqueiro Hospital, Galicia Sur Health Research Institute (IIS Galicia Sur), Complexo Hospitalario Universitario de Vigo, SERGAS-UVigo, Vigo, Spain

    1 shared publication
  • Ana Serna-Gallego

    Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville, IBiS, Virgen del Rocío University Hospital/CSIC/University of Seville, 41013 Seville, Spain

    1 shared publication
  • Ciara Kathleen O'SUllivan

    INTERFIBIO Consolidated Research Group, Departament d’Enginyeria Química, Universitat Rovira i Virgili, Tarragona, Spain

    1 shared publication
  • Cristina Martínez-Reglero

    Methodology and Statistics Unit, Galicia Sur Health Research Institute (IISGS), 36312 Vigo, Spain

    1 shared publication
  • Esperanza Muñoz-Muela

    Clinical Unit of Infectious Diseases, Microbiology and Parasitology, Institute of Biomedicine of Seville, University Hospital Virgen del Rocío, Higher Council for Scientific Research, University of Seville , Seville

    1 shared publication
  • Eva Poveda

    Virology and Pathogenesis Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), Complexo Hospitalario Universitario de Vigo, SERGAS-UVIGO, Vigo, Spain

    1 shared publication

Latest Publications

  • Open Access

    Elevated Anti-SARS-CoV-2 Antibodies and IL-6, IL-8, MIP-1β, Early Predictors of Severe COVID-19

    by Helena Codina, Irene Vieitez, Alicia Gutierrez-Valencia, Vasso Skouridou, Cristina Martínez, Lucía Patiño, Mariluz Botero-Gallego, María Trujillo-Rodríguez, Ana Serna-Gallego, Esperanza Muñoz-Muela, et al.

    Viral and host immune kinetics during acute COVID-19 and after remission of acute symptoms need better characterization. SARS-CoV-2 RNA, anti-SARS-CoV-2 IgA, IgM, and IgG antibodies, and proinflammatory cytokines were measured in sequential samples from hospitalized COVID-19 patients during acute infection and six months following diagnosis. Twenty four laboratory confirmed COVID-19 patients with mild/moderate and severe COVID-19 were included. Most were males (83%) with a median age of 61 years. Twenty one percent were admitted to the intensive care unit (ICU) and eight of them (33.3%) met the criteria for severe COVID-19 disease. A delay in SARS-CoV-2 levels’ decline during the first six days of follow up, and viral load persistence until month 3 were related to severe COVID-19, but not viral load levels at the diagnosis. Higher levels of anti-SARS-CoV-2 IgA, IgM, IgG and the cytokines IL-6, IL-8 and MIP-1β at the diagnosis time were related to the severe COVID-19 outcome. Higher levels of MIP-1β, IL-1β, MIP-1α and IFN-γ were observed at month 1 and 3 during mild/moderate disease, compared to severe COVID-19. IgG persisted at low levels after six months of diagnosis. In conclusion, higher concentrations of IgA, IgM, and IgG, and IL-6, IL-8 and MIP-1β are identified as early predictors of COVID-19 severity, whereas no significant association is found between baseline SARS-COV-2 viral load and COVID-19 severity.